For example, in advanced tumors where tumor cells tend to evade anti-tumor responses by downregulating major histocompatibility complexes (MHC), minimizing CD80/86 on tumor cells may be redundant as APCs remain the only targets of Tregs. The gene discussed is HLA-C; the disease is neoplasm.